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Background: Silent and overt ischemic brain lesions are common and associated
with adverse outcome. Whether the CHA2DS2-VASc score and its components predict
magnetic resonance imaging (MRI)-detected ischemic silent and overt brain lesions in
patients with atrial fibrillation (AF) is unclear.
Methods: In this cross-sectional analysis, patients with AF were enrolled in a multicenter
cohort study in Switzerland. Outcomes were clinically overt, silent [in the absence of a
history of stroke/transient ischemic attack (TIA)] and any MRI-detected ischemic brain
lesions. Logistic regression analyses were performed to assess the relationship of the
CHA2DS2-VASc score and its components with ischemic brain lesions. An adapted
CHA2D-VASc score (excluding history of stroke/TIA) for the analyses of clinically overt
and silent ischemic brain lesions was used.
Results: Overall, 1,741 patients were included in the analysis (age 73 ± 8 years,
27.4% female). At least one ischemic brain lesion was observed in 36.8% (clinically
overt: 10.5%; silent: 22.9%; transient ischemic attack: 3.4%). The CHA2D-VASc
score was strongly associated with clinically overt and silent ischemic brain lesions
{odds ratio (OR) [95% confidence interval (CI)] 1.32 (1.17–1.49), p < 0.001 and
1.20 (1.10–1.30), p < 0.001, respectively}. Age 65–74 years (OR 2.58; 95%CI
1.29–5.90; p = 0.013), age ≥75 years (4.13; 2.07–9.43; p < 0.001), hypertension
(1.90; 1.28–2.88; p = 0.002) and diabetes (1.48; 1.00–2.18; p = 0.047) were
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associated with clinically overt brain lesions, whereas age 65–74 years (1.95; 1.26–3.10;
p = 0.004), age ≥75 years (3.06; 1.98–4.89; p < 0.001) and vascular disease (1.39;
1.07–1.79; p = 0.012) were associated with silent ischemic brain lesions.
Conclusions: A higher CHA2D-VASc score was associated with a higher risk of both
overt and silent ischemic brain lesions.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02105844.
Keywords: atrial fibrillation, silent ischemic brain lesion, stroke, CHA2DS2-VASc score, ischemic brain lesion
INTRODUCTION
Patients with atrial fibrillation (AF) have a high risk of stroke,
heart failure and death (1–3). Recent evidence suggests that
patients with AF have a substantial burden of silent brain infarcts,
detected only by magnetic resonance imaging (MRI) (4, 5). In
a contemporary cohort of AF patients, the prevalence of silent
infarcts was 25.7%. Currently, there is only limited data on risk
factors for silent ischemic brain lesions in this group of patients
(4). Since silent ischemic brain lesions are highly prevalent
and have been reported to be strongly related with cognitive
dysfunction and an increased risk of future symptomatic stroke
(6), a better understanding of the potential risk factors is crucial
for prevention and possible treatment strategies (4, 7).
The CHA2DS2-VASc score is an aggregate of modifiable
and non-modifiable risk factors and has been developed to
predict the individual stroke risk in patients with AF and to
aid in the decision whether oral anticoagulation is warranted
(8, 9). Although the CHA2DS2-VASc score is a commonly used
clinical tool to risk stratify AF patients for future strokes, it is
unclear whether and to what extent the score and its individual
components are associated with the presence of imaging detected,
clinically overt or silent ischemic brain lesions in patients with
AF. Identifying the individual modifiable risk factors for silent
ischemic brain lesions in AF patients may be relevant in order
to take preventive measures at an early stage and improve the
prevention of stroke and its sequelae in AF patients. Additionally,
the predictive performance of the CHA2DS2-VASc score to detect
ischemic silent or overt brain lesions is not yet known.
Therefore, the aim of the current study was to investigate the
association and the predictive value of the CHA2DS2-VASc score,
and specifically its individual components, with clinically overt or
silent ischemic brain lesions detected onMRI, in a large cohort of
AF patients mainly on oral anticoagulation.
METHODS
Study Population
The analysis is based on data from the Swiss Atrial Fibrillation
Cohort (Swiss-AF), an ongoing prospective, observational,
multicenter cohort study. Overall, 2,415 patients with
documented AF were enrolled between 2014 and 2017 across
14 centers in Switzerland. The main inclusion criteria were
previously documented AF and age ≥65 years (a subgroup of
10% was aged between 45 and 65 years). Patients were excluded
if they had short secondary, reversible episodes of AF (e.g., after
cardiac surgery), had an acute illness within the last 4 weeks or
were unable to sign informed consent (10). The study protocol
has been approved by the local ethic committees, and written
informed consent was obtained from each participant.
Of the 2,415 patients enrolled, 674 (27.9%) were excluded
due to missing brain MRI (n = 667, 27.6%), or missing data
on ischemic brain lesions at baseline visit (n = 5, 0.2%),
or missing information on the CHA2DS2-VASc score (n =
2, 0.1%), resulting in 1,741 patients (72.1%) for this analysis
(Supplementary Figure 1). Themain reasons for not performing
brain MRI were the presence of a cardiac implantable electronic
device and claustrophobia.
Study Procedures
Information on individual patient characteristics, medical history
and current medication were collected using standardized case
report forms. Body height and weight were measured at baseline,
and body mass index (BMI) was calculated by dividing weight
in kilograms by height in meters squared. Blood pressure
was measured three times in supine position and the mean
was calculated for this analysis. AF type was categorized as
paroxysmal, persistent, or permanent according to the guidelines
of the European Society of Cardiology (11).
Brain Magnetic Resonance Imaging and
Ischemic Brain Lesions
Brain magnetic resonance imaging (MRI) was performed using a
1.5 or 3 Tesla whole body scanner. The standardized acquisition
protocol included a 3D T1 weighted (T1w) Magnetization
Prepared Rapid Gradient Echo (MPRAGE) and a 2D axial fluid
attenuated inversion recovery (FLAIR). Acquired MRI scans
were transferred to an imaging clinical research organization
specialized in international phase III pharmacological treatment
trials (Medical Image Analysis Centre, Basel, Switzerland).
Brain lesions were marked and segmented in a standardized
fashion using Amira (Mercury Computer Systems Inc.,
Chelmsford, USA) by trained and validated raters and
subsequently confirmed by expert readers. All investigators
were blinded of the clinical evolution of the patients. Ischemic
brain lesions were identified by their characteristic lesion
morphology on both FLAIR and T1w images. Next, ischemic
brain lesions were separated into small non-cortical infarcts
or large non-cortical and cortical infarcts. Hereby, FLAIR-
hyperintense lesions with low signal on T1w MPRAGE and a
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FIGURE 1 | Brain magnetic resonance imaging showing (A) small non-cortical infarct (B) small cortical infarcts, and (C) large non-cortical and cortical infarcts.
diameter of ≤20mm, not involving the cortex, were defined as
small non-cortical infarcts (SNCI). Possible localizations of SNCI
were white matter, internal or external capsule, deep brain nuclei,
thalamus and brainstem. Perivascular spaces were excluded by
their tubular spatial appearance. Non-cortical infarcts with a
diameter of >20mm were defined as large non-cortical infarcts,
whereas cortical infarcts were FLAIR-hyperintense lesions of
any size, involving the cortex. Both ischemic lesion types are
classified as large non-cortical and cortical infarcts (LNCCI) (4).
Based on the MRI, the etiology of the ischemic lesion cannot be
proven. However, it can be assumed, that LNCCI more likely
occur due to embolic events, whereas SNCI are corresponding
to microvascular brain damage. Any ischemic brain lesions were
defined as either LNCCI or SNCI. Examples of SNCI, small
cortical infarcts and LNCCI are presented in Figure 1.
Outcome Events
The main outcome was the prevalence of ischemic brain lesions
on MRI. “Clinically overt ischemic brain lesions” were defined
as MRI-detected ischemic brain lesions in patients with a history
of stroke. “Silent ischemic brain lesions” were defined as MRI-
detected ischemic brain lesions in patients without a history of
stroke or transient ischemic attack (TIA). “Any ischemic brain
lesion” was defined as a composite of clinically overt and silent
ischemic brain lesions. Since it was assumed that TIA does not
cause MRI-detectable brain infarction, detected brain lesions in
patients with a history of TIA were not classified as clinically
overt or silent, but were considered in the composite outcome
of any ischemic brain lesion (12).
Adaption of the CHA2DS2-VASc Score
Themain objective of this study was to investigate the association
of the CHA2DS2-VASc score with clinically overt and silent
ischemic brain lesions. For the purpose of this analysis, we
therefore excluded the “S2” (history of stroke or TIA) component
from the CHA2DS2-VASc score, and used an adapted CHA2D-
VASc score comprising the following variables: history of heart
failure, history of hypertension, age of 65–74 years and age
≥75 years, history of diabetes, vascular disease [including
history of myocardial infarction, history of coronary artery
disease, history of coronary artery bypass graft (CABG), history
of percutaneous coronary intervention (PCI)/stenting, history
of peripheral vascular disease] and female sex. Each variable
corresponded to 1 point each, except age ≥75 years, which
counted as 2 points. The total score ranged from 0 (low risk) to
7 (high risk). We used the CHA2D-VASc score for analyses with
clinically overt, silent and any ischemic brain lesion. For analyses
with the outcome of any ischemic brain lesion, we additionally
used the conventional CHA2DS2-VASc score. In both scores we
assigned 0 points to female patients who had no further risk
factors (9). We grouped together patients with a CHA2D-VASc
score ≥5, due to their small number in our cohort.
Statistical Analysis
Baseline characteristics were stratified by the presence or absence
of a history of stroke. Numbers are presented as counts
(percentages) for categorical variables or means (± standard
deviation) for continuous variables. Groups were compared
using Chi-square tests for categorical variables, and Student’s
t-tests or Mann-Whitney-U-test for continuous variables, as
appropriate. Prevalence of clinically overt and silent ischemic
brain lesions was stratified according to the CHA2D-VASc score
and presented as numbers (percentage).
To investigate the associations of the CHA2D-VASc score
with ischemic brain lesions, we performed multivariable
logistic regression analyses to calculate the odds ratio (OR)
and corresponding 95% confidence interval (CI). Presence of
clinically overt, silent and any ischemic brain lesions were used
as binary outcome variables. For any ischemic brain lesion,
additional analyses were performed using the CHA2DS2-VASc
score. In addition, the association of the CHA2D-VASc score
and the CHA2DS2-VASc score with LNCCI and SNCI was
investigated using logistic regression models. All multivariable
models were adjusted for BMI, smoking status, renal function,
history of venous thromboembolism, history of systemic arterial
embolism, AF type and intake of oral anticoagulation.
The goodness-of fit of the CHA2D-VASc score to predict
clinically overt, silent or any ischemic brain lesions was compared
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TABLE 1 | Baseline characteristics stratified by presence or absence of history of stroke.
Characteristic All patients
(n = 1,741)
Patients with history of stroke
(n = 230)
Patients without history of stroke
(n = 1,511)
P-value*
Age, yrs 72.5 ± 8.4 74.9 ± 7.0 72.0 ± 8.6 <0.001
Female sex 477 (27.4%) 70 (30.4%) 407 (26.9%) 0.30
BMI, kg/m2 27.7 ± 4.8 27.7 ± 4.9 27.7 ± 4.7 0.95
Smoking status† 0.99
Current 132 (7.6%) 18 (7.8%) 114 (7.6%)
Past 840 (48.3%) 111 (48.3%) 729 (48.3%)
Never 767 (44.1%) 101 (43.9%) 666(44.1%)
Systolic blood pressure‡, mm Hg 135 ± 19 135 ±19 135 ± 18 0.70
Diastolic blood pressure‡, mm Hg 78 ± 12 77 ± 12 79 ± 12 0.03
AF type 0.008
Paroxysmal 799 (45.9%) 175 (50.3%) 624 (44.8%)
Persistent 524 (30.1%) 81 (23.3%) 443 (31.8%)
Permanent 418 (24.0%) 92 (26.4%) 326 (23.4%)
History of heart failure 378 (21.7%) 56 (24.3%) 322 (21.3%) 0.34
History of hypertension 1199 (68.9%) 178 (77.4%) 1021 (67.6%) 0.004
History of diabetes mellitus 271 (15.6%) 49 (21.3%) 222 (14.7%) 0.01
History of TIA 159 (9.1%) 41 (17.8%) 118 (7.8%) <0.001
History of coronary heart disease 462 (26.5%) 67 (29.1%) 395 (26.1%) 0.38
History of peripheral vascular disease 122 (7.0%) 18 (7.8%) 104 (6.9%) 0.70
History of deep venous thrombosis/ pulmonary embolism 151 (8.7%) 22 (9.6%) 129 (8.5%) 0.97
History of bleeding† 246 (14.1%) 44 (19.1%) 202 (13.4%) 0.03
History of renal failure§ 313 (18.0%) 48 (20.9%) 265 (17.5%) 0.26
CHA2DS2-VASc score 3.3 ± 1.7 5.3 ± 1.3 3.0 ± 1.6 <0.001
Oral anticoagulation 1,569 (90.1%) 217 (94.3%) 1,352 (89.5%) 0.03
Vitamin K antagonists (VKA) 634 (36.4%) 87 (37.8%) 547 (36.2%) 0.69
Direct oral anticoagulants (DOAC) 934 (53.6%) 130 (56.5%) 804 (53.2%) 0.38
Antiplatelet therapy|| 306 (17.6%) 50 (21.9%) 256 (17.0%) 0.08
Previous pulmonary vein isolation 394 (22.6%) 24(10.4%) 370 (24.5%) <0.001
AF, atrial fibrillation; BMI, body-mass index; TIA, transient ischemic attack.
Data are presented as means (± standard deviation) or numbers (percentage), as appropriate.
CHA2DS2-VASc= congestive heart failure, hypertension, age≥75 yrs (2 points), diabetes, prior stroke or TIA or thromboembolism (2 points), vascular disease, age 65–74 yrs, female sex.
*P-value compares the values between patients with or without history of stroke. Groups were compared using a Chi-squared test for categorical variables and Student’s t-test or
Mann-Whitney-U-test for continuous variables.
†n = 2 missings, ‡n = 10 missings, §n = 1 missing, ||n = 3 missings.
based on the Akaike Information Criteria (AIC) and the Brier
score. A similar approach was used for the CHA2DS2-VASc
score to predict any ischemic brain lesion. The discriminative
ability of both scores was assessed by calculating the c-
statistic. We compared the predictive performance of different
models, excluding each component of the CHA2D-VASc score
in turn.
Furthermore, logistic regression analysis was performed to
determine the association between each component of the
CHA2D-VASc score and ischemic brain lesions. A combined
model (model 1) was used, including all individual components
of the CHA2D-VASc score. For the outcome of any ischemic
brain lesion, we performed an additional analysis including all
components of the CHA2DS2-VASc score in the combinedmodel
(model 2). Co-linearity in all combined models was evaluated
using the variation inflation factor (VIF). Statistical analyses were
performed using R Studio (Version 3.6.1).
RESULTS
Baseline characteristics are presented in Table 1. Mean age of this
AF population was 73 ± 8 years, and 477 (27.4%) were female.
The mean CHA2DS2-VASc score was 3.3 ± 1.7. Overall, 230
(13.2%) patients had a history of stroke. Patients with a history
of stroke were older (75 ± 7 vs. 72 ± 9 years; p < 0.001), more
frequently had hypertension (77.4 vs. 67.6%; p= 0.004), diabetes
(21.3 vs. 14.7%; p = 0.01) and a history of bleeding (19.1 vs.
13.4%; p= 0.03) compared to patients without a history of stroke.
The great majority of patients were anticoagulated, but patients
with a history of stroke were more often on oral anticoagulation
compared to patients without a history of stroke (94.3 vs. 89.5%;
p= 0.03).
The prevalence of ischemic brain lesions stratified by the
CHA2D-VASc score is shown in Figure 2. Overall, 641 (36.8%)
patients had at least one ischemic brain lesion. Of those, 399
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FIGURE 2 | Prevalence of ischemic brain lesions stratified by the adapted CHA2D-VASc score.
Abbreviations: TIA, transient ischemic attack.
aExcluding history of stroke/TIA (S2).
Female patients with a CHA2D-VASc score of 1 were assigned to the category of CHA2D-VASc score 0.
Clinically overt ischemic brain lesions were defined as ischemic brain lesions in patients with a history of stroke.
Silent ischemic brain lesions were defined as ischemic brain lesions in patients without a history of stroke/TIA.
(22.9%) were silent and 183 (10.5%) were clinically overt,
whereby 59 (3.4%) patients with an ischemic brain lesion had
a history of TIA. When distinguishing between the type of
ischemic brain lesions, 390 (22.4%) had LNCCI and 373 (21.4%)
had SNCI (Supplementary Table 1). The prevalence of ischemic
brain lesions was increasing with a higher CHA2D-VASc score
with the highest prevalence in patients with a risk score of ≥5.
Using the CHA2D-VASc score as an ordinal variable, we found
linear relationships with clinically overt, silent and any ischemic
lesions in a multivariable model (Table 2). Per 1 point increase
in the adapted score, the multivariable adjusted OR (95% CI)
for clinically overt ischemic brain lesions, silent ischemic brain
lesions or any ischemic brain lesion were 1.32 (1.17–1.49; p <
0.001), 1.20 (1.10–1.30; p < 0.001) and 1.33 (1.23–1.44; p <
0.001), respectively. In each of the individual score categories
of the CHA2D-VASc score, ORs were higher for clinically overt
ischemic brain lesions compared to silent ischemic brain lesions.
The results of the association of the CHA2D-VASc score with
LNCCI and SNCI are presented in Supplementary Table 1. Per
1-point increase in CHA2D-VASc score, the OR (95% CI) for the
presence of LNCCI or SNCI was 1.22 (1.12; 1.33), p < 0.001 and
1.37 (1.25; 1.50), p < 0.001.
The predictive performance of the risk score for ischemic
brain lesions is shown in Table 3. The C-statistic of the CHA2D-
VASc score was 0.62 for clinically overt ischemic brain lesions
and 0.58 for silent ischemic brain lesions. Compared to the
CHA2DS2-VASc score, the CHA2D-VASc score had a lower C-
statistic (0.63 vs. 0.69) and a higher AIC (2,217 vs. 2,099) and a
higher Brier score (0.223 vs. 0.207) for predicting any ischemic
brain lesion.
Associations of the individual components of the CHA2D-
VASc score and clinically overt, silent and any ischemic brain
lesions are presented in Table 4. History of hypertension (OR
1.90; 95% CI 1.28–2.88; p = 0.002), age between 65 and 74 years
(OR 2.58; 95% CI 1.29–5.90; p = 0.013), age ≥75 years (OR
4.13; 95% CI 2.07–9.43; p < 0.001) and history of diabetes (OR
1.48; 95% CI 1.00–2.18; p= 0.047) were associated with clinically
overt ischemic brain lesions, but vascular disease, heart failure
and female sex were not.
Risk factors associated with silent ischemic brain lesions were
age between 65 and 74 years (OR 1.95; 95% CI 1.26–3.10; p =
0.004), age ≥75 years (OR 3.06; 95% CI 1.98–4.89; p < 0.001)
and history of vascular disease (OR 1.39; 95% CI 1.07–1.79; p
= 0.012), but history of heart failure, hypertension, diabetes and
female sex were not significantly associated with silent ischemic
brain lesions. Risk factors associated with any ischemic brain
lesion included age between 65 and 74 years (OR 2.51; 95% CI
1.72–3.77; p < 0.001), age≥75 years (OR 4.71; 95% CI 3.20–7.10;
p< 0.001) and history of vascular disease (OR 1.31; 95% CI 1.04–
1.64; p = 0.026). However, history of heart failure, hypertension,
diabetes and female sex were not significantly associated with
any ischemic brain lesion. When adding history of stroke/TIA to
the combined model (Model 2) for the outcome of any ischemic
brain lesion, a strong association between history of stroke/TIA
and any ischemic brain lesion was observed (OR 5.30; 95% CI
4.08–6.93; p < 0.001).
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TABLE 2 | Relationship of the risk score with ischemic brain lesions.
Adjusted Odds ratio (95% CI)*, p-value
Clinically overt ischemic brain lesions (n = 183) Silent ischemic brain lesions (n = 399) Any ischemic brain lesion (n = 641)
CHA2D-VASc score
† 1.32 (1.17, 1.49), p < 0.001 1.20 (1.10, 1.30), p < 0.001 1.33 (1.23, 1.44), p < 0.001
CHA2DS2-VASc score NA NA 1.52 (1.42, 1.62), p < 0.001
CHA2D-VASc score
†
≤1 1 (Reference) 1 (Reference) 1 (Reference)
2 1.76 (0.90, 3.67), p = 0.11 1.30 (0.87, 1.96), p = 0.21 1.40 (0.98, 2.01), p = 0.07
3 2.71 (1.46, 5.44), p = 0.003 1.49 (1.01, 2.21), p = 0.05 2.06 (1.47, 2.91), p < 0.001
4 4.15 (2.23, 8.35), p < 0.001 1.94 (1.30, 2.92), p = 0.001 3.07 (2.16, 4.41), p < 0.001
≥5 3.67 (1.85, 7.73), p < 0.001 2.22 (1.43, 3.46), p < 0.001 3.20 (2.16, 4.79), p < 0.001
NA, not applicable.
*Multivariable models were adjusted for body mass index, smoking status, renal function, and history of deep venous thrombosis/pulmonary embolism, history of systemic embolism,
atrial fibrillation type and oral anticoagulation, n = 3 missings.
†CHA2D-VASc score was adapted by excluding history of stroke/transient ischemic attack (S2 ).
Female patients with a CHA2D-VASc score/CHA2DS2-VASc score of 1 were assigned to the category of 0 points.
Clinically overt ischemic brain lesions were defined as ischemic brain lesions in patients with a history of stroke.
Silent ischemic brain lesions were defined as ischemic brain lesions in patients without a history of stroke/TIA.
Any ischemic brain lesion was defined as a composite of clinically overt and silent ischemic brain lesions including ischemic lesions in patients with history of TIA.
TABLE 3 | Predictive performance of the risk score for ischemic brain lesions.
CHA2D-VASc score* CHA2DS2-VASc score
Clinically overt ischemic brain lesions
C-statistic 0.622 NA
Brier Score 0.093 NA
AIC 1,147 NA
Silent ischemic brain lesions
C-statistic 0.582 NA
Brier Score 0.174 NA
AIC 1,852 NA
Any ischemic brain lesion
C-statistic 0.626 0.693
Brier Score 0.223 0.207
AIC 2,217 2,099
AIC, Akaike’s Information Criteria; NA, not applicable.
*CHA2D-VASc score was adapted by excluding history of stroke/transient ischemic
attack (S2 ).
Female patients with a CHA2D-VASc score/CHA2DS2-VASc score of 1 were assigned to
the category of 0 points.
Clinically overt ischemic brain lesions were defined as ischemic brain lesions in patients
with a history of stroke.
Silent ischemic brain lesions were defined as ischemic brain lesions in patients without a
history of stroke/TIA.
Any ischemic brain lesion was defined as a composite of clinically overt and silent ischemic
brain lesions including ischemic lesions in patients with history of TIA.
The impact of individual CHA2D-VASc components to the
full CHA2D-VAScmodel is presented in Supplementary Table 2.
DISCUSSION
In this study investigating the associations between the CHA2D-
VASc score and ischemic brain lesions in a cohort of
well-characterized AF patients, the following main findings
emerged: First, in this population of AF patients, the prevalence
of ischemic brain lesions was high, and two thirds of all brain
lesions were observed in patients without a history of stroke
or TIA. Second, a higher CHA2D-VASc score was associated
with a higher prevalence of ischemic brain lesions detected by
MRI compared to lower scores. Third, the CHA2D-VASc score
was associated not only with clinically overt but also with silent
ischemic brain lesions. Fourth, the individual components of
the CHA2D-VASc score showed slightly differential associations
with clinically overt compared to silent ischemic brain lesions.
Finally, both female sex and heart failure were not associated
with clinically overt, silent or any ischemic brain lesions in any
of the models.
In our study of mainly anticoagulated patients, the CHA2D-
VASc score was linearly associated with the presence of silent and
overt ischemic brain lesions. This is in line with the results of
smaller studies in patients with aortic stenosis and low risk AF
patients (13, 14). In addition, we found a strong association of the
CHA2D-VASc score with the two different brain lesion categories
of LNCCI and SNCI.
Increasing age, hypertension and diabetes mellitus are
conventional risk factors for ischemic stroke (15). In our cohort,
we found similar associations. Age of ≥ 65 years was an
important risk factor not only for clinically overt, but for silent
ischemic brain lesions as well, which is in line with findings from
other epidemiologic studies (8, 14, 16).
We have found that the presence of vascular disease was
associated with silent ischemic brain lesions. Prior studies have
suggested that cerebral small vessel disease plays an important
role in the pathogenesis of silent brain infarcts (17, 18). Cerebral
small vessel disease is defined as segmental atherosclerotic
disorganization of the small perforating arteries, which leads to
a process of ischemia and infarction, resulting in tissue damage
and lacunar scar formation (18). The vascular disease burden in
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TABLE 4 | Relationship of the individual components and ischemic brain lesions.
Clinically overt ischemic brain lesions
(n = 183)
Silent ischemic brain lesions
(n = 399)
Any ischemic brain lesion
(n = 641)
No. of Cases Odds ratio
(95% CI)
No. of Cases Odds ratio
(95% CI)
No. of Cases Odds ratio
(95% CI)
Components Model 1* Model 1* Model 1* Model 2†
History of heart failure 46 0.96 (0.66, 1.39) 109 1.31 (0.99, 1.71) 168 1.19 (0.93, 1.53) 1.24 (0.96, 1.61)
History of hypertension 150 1.90 (1.28, 2.88) 279 0.87 (0.67, 1.12) 473 1.15 (0.92, 1.45) 1.11 (0.87, 1.42)
Age
65–74 years‡ 72 2.58 (1.29, 5.90) 161 1.95 (1.26, 3.10) 256 2.51 (1.72, 3.77) 2.16 (1.46, 3.29)
≥75 years§ 103 4.13 (2.07, 9.43) 212 3.06 (1.98, 4.89) 350 4.71 (3.20, 7.10) 3.99 (2.67, 6.09)
History of diabetes 42 1.48 (1.00, 2.18) 69 0.98 (0.71, 1.34) 120 1.16 (0.87, 1.53) 1.09 (0.81, 1.46)
History of vascular disease 61 0.90 (0.63, 1.28) 153 1.39 (1.07, 1.79) 237 1.31 (1.04, 1.64) 1.30 (1.02, 1.65)
Female sex 52 0.99 (0.69, 1.41) 96 0.79 (0.60, 1.04) 165 0.84 (0.66, 1.06) 0.77 (0.60, 0.99)
History of stroke/TIA|| 242 5.30 (4.08, 6.93)
CI, confidence interval; TIA, transient ischemic attack.
*Model 1: The model was combined including all components of the CHA2D-VASc score (history of heart failure, history of hypertension, age 65–74 years and ≥75 years, history of
diabetes, vascular disease and female sex).
†Model 2: The model was combined including all components of the CHA2DS2-VASc score (history of heart failure, history of hypertension, age 65–74 years and ≥75 years, history of
diabetes, vascular disease and female sex and history of stroke/TIA).
Clinically overt ischemic brain lesions were defined as ischemic brain lesions in patients with a history of stroke.
Silent ischemic brain lesions were defined as ischemic brain lesions in patients without a history of stroke/TIA.
Any ischemic brain lesion was defined as a composite of clinically overt and silent ischemic brain lesions including ischemic lesions in patients with history of TIA.
‡n = 789, §n = 722, ||n = 348.
our cohort may suggest coexisting small vessel disease, which in
turn is associated with silent ischemic brain lesions. In addition,
hypertension, considered one of the most important causes of
cerebral small vessel disease (18), was a strong predictor for silent
ischemic brain lesions in several studies (16, 19). Interestingly,
in our cohort, although associated with clinically overt ischemic
brain lesions, hypertension was not associated with silent brain
lesions. This finding may be explained by the fact that measured
systolic blood pressure in our cohort was nearly 20 mmHg lower
compared to other study populations (20, 21)
Female sex was neither associated with clinically overt nor
with silent ischemic brain lesions in our cohort, which is in
contrast to other reports suggesting that women have a higher
risk of (overt) stroke than men (15, 22). Regarding silent
ischemic brain lesions, analyses from the Atherosclerosis Risk
in Communities Study showed that female sex was not related
to an increased risk of silent brain infarcts (23). Similarly, in
the Rotterdam Scan Study, female sex was associated with silent
ischemic brain lesions in age and sex adjusted models, but
not after adjustments for additional covariates (20). Our results
suggest that risk stratification for stroke using the CHA2DS2-
VASc scheme without female sex as a risk factor is debatable,
since female sex may be considered as a risk modifier rather
than a risk factor in stroke risk assessment (24). Given the
heterogeneity of study results on sex as a potential independent
risk factor, further research is needed to identify potential sex-
specific differences in the development of silent brain infarcts
(20, 23).
Neither clinically overt nor silent ischemic brain lesions were
associated with a history of heart failure in our population.
This interrelationship has been investigated in recent studies,
suggesting that heart failure per se may not be a strong
predictor for clinically overt ischemic brain lesions (8, 15).
These findings are also supported by the results of a recent trial
showing that patients with diagnosed heart failure, albeit without
known AF, do not benefit from oral anticoagulation for stroke
prevention (25).
In clinical practice, the CHA2DS2-VASc score is used for risk
assessment with the purpose of the prevention of stroke, whereas
a history of stroke or TIA in AF patients corresponds to 2 points
according to the CHA2DS2-VASc scheme, these patients qualify
for secondary prevention using oral anticoagulation independent
of their stroke risk based on the CHA2DS2-VASc score.
Therefore, regarding primary prevention, excluding the “history
of stroke” component from the score could be considered, as
it artificially increases the apparent discriminative ability to
predict ischemic brain lesions. Since MRI was performed in
this study, providing information on clinically overt and silent
brain infarcts, we performed risk stratification using a CHA2D-
VASc score and analyzed its predictive value for clinically overt,
silent and any ischemic brain lesion. The modest reported C-
statistics show that additional tools for better risk prediction
would be desirable. Stroke prediction can be improved slightly
by additional use of biomarkers, but whether a biomarker score
guided approach improves outcomes is unknown but currently
tested in a randomized trial (26).
Our findings also underscore the importance of gaining
knowledge in specific causes for silent ischemic brain lesions in
patients with AF. Currently, we might underestimate the risk
of silent ischemic strokes in AF patients. As the prevalence of
silent ischemic brain lesions is shown to be associated with a
higher risk for future symptomatic stroke, a screening tool for
the detection of silent ischemic brain lesions might be justified
to evaluate stroke risk even in lower risk AF patients (5, 6).
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However, the clinical value of such an approach would need
to be tested in a prospective study. Additionally, given that
silent ischemic brain lesions are independently associated with
cognitive dysfunction, identifying additional factors beyond the
CHA2DS2-VASc score that may contribute to the development
of these lesions is imperative (4).
STRENGTHS AND LIMITATIONS
The major strengths of our study are the large and well-
characterized community-based cohort of AF patients and the
very low rate of missing values. Additionally, brain MRIs
were acquired and validated centrally using standard operating
procedures. However, some potential limitations need to be
considered. First, given the observational design of the study,
causality of the associations cannot be inferred. Second, clinical
presentation of previous stroke was not systematically evaluated.
Therefore, we could not distinguish which lesions were actually
associated with the overt stroke and which were silent in patients
with multiple ischemic brain lesions and a positive stroke
history. Third, our cohort does not represent a treatment-naïve
patient group because the vast majority of patients were on oral
anticoagulation. However, it also reflects the level of care in a
country with a high standard in healthcare and therefore most
likely daily practice in developed countries. Finally, due to the
study design, it could not be determined whether the ischemic
brain lesion occurred before or after anticoagulation was started.
CONCLUSION
In conclusion, we found that an increasing CHA2D-VASc score
was associated with a higher prevalence of ischemic brain lesions
in AF patients. The predictive value of the CHA2D-VASc score
was modest both for clinically overt and silent ischemic brain
lesions. Differential associations of the individual components of
the score were observed for clinically overt compared to silent
ischemic brain lesions.
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